A descriptive study of commercial herbal dietary supplements used for dyslipidemia-Sales data and suspected adverse reactions.
dyslipidemia
herbal dietary supplement
monacolin K
red yeast rice
sales data
suspected adverse reactions
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
01
04
2022
received:
13
12
2021
accepted:
03
04
2022
pubmed:
8
5
2022
medline:
22
6
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Herbal dietary supplements (HDS) used for dyslipidemia represent a category of concern in Italy for suspected adverse reactions (ARs). However, we cannot estimate their safety, as we do not know their commercial profile. Sales data of HDS, and particularly, those used for dyslipidemia, were monitored for 2 years in two pharmacies of Rome. Meanwhile, spontaneous reports of suspected ARs potentially related to dyslipidemia supplements were collected by the Italian Phytovigilance System. The 50% of the total dietary supplements are herbal-derived; the 9% of HDS are recommended for dyslipidemia. From our data, 113 different brands have claims for improving lipids profile and 91% of them are multiingredient preparations. Fifteen spontaneous reports of suspected ARs concerned HDS used, for dyslipidemia. The most frequent ARs were joint, abdominal, and muscles pain; vomiting; erythema and hematological disorders; nausea; and rhabdomyolysis. Our findings point out the limited compliance of commercial dyslipidemia-HDS and scientific research about their intrinsic safety. A wide range of ingredients could not support the risk/benefit profile of the supplement. The variable compositions of HDS do not assure the safety, as they do not support the reproducibility of their pharmacological activities. This study could contribute to optimize consumer guidance about what they purchase and consume.
Identifiants
pubmed: 35524700
doi: 10.1002/ptr.7473
pmc: PMC9321615
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2583-2604Informations de copyright
© 2022 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.
Références
Ann Ist Super Sanita. 2020 Oct-Dec;56(4):462-469
pubmed: 33346172
Crit Rev Food Sci Nutr. 2021;61(6):906-919
pubmed: 32274931
Phytother Res. 2012 Mar;26(3):317-24
pubmed: 22095937
Planta Med. 2020 Jan;86(2):132-143
pubmed: 31784970
Eur J Clin Pharmacol. 2011 Mar;67(3):215-24
pubmed: 21243344
Arch Med Sci. 2015 Apr 25;11(2):253-66
pubmed: 25995739
Arch Med Sci. 2017 Aug;13(5):965-1005
pubmed: 28883839
Life Sci. 2020 Aug 1;254:117756
pubmed: 32389832
Int J Health Plann Manage. 2021 Jul;36(4):1370-1372
pubmed: 33890337
Nutrients. 2021 Feb 16;13(2):
pubmed: 33669333
Br J Clin Pharmacol. 2017 Apr;83(4):894-908
pubmed: 28093797
Phytother Res. 2018 Jul;32(7):1163-1180
pubmed: 29575316
Eur J Clin Nutr. 2017 Dec;71(12):1381-1392
pubmed: 28145414
Phytother Res. 2022 Jun;36(6):2583-2604
pubmed: 35524700
EFSA J. 2018 Aug 03;16(8):e05368
pubmed: 32626016
Crit Rev Food Sci Nutr. 2019;59(8):1334-1346
pubmed: 29236516
Food Chem Toxicol. 2016 Oct;96:145-54
pubmed: 27498339
Am J Clin Nutr. 2018 Nov 1;108(5):922-932
pubmed: 30239559
J Sci Food Agric. 2017 May;97(7):2107-2115
pubmed: 27571713
Nutrients. 2020 Oct 14;12(10):
pubmed: 33066334
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Ann Agric Environ Med. 2021 Mar 18;28(1):81-88
pubmed: 33775071
Pharmacol Res. 2016 Dec;114:42-46
pubmed: 27751878
Nutr J. 2017 Oct 11;16(1):68
pubmed: 29020971